Type:10 Tablets
Generic Name:Aspirin
Manufacturer:The ACME Laboratories Ltd.
Price:৳8.00
PO Prophylaxis of myocardial infarction Adult: 75-300 mg once daily. Lower doses should be used in patients receiving ACE inhibitors. Stent implantation Adult: 300 mg 2 hr before procedure followed by 150-300 mg/day thereafter. Mild to moderate pain and fever Adult: 150-300 mg repeated every 4-6 hr according to response. Max: 4 g/day. Pain and inflammation associated with musculoskeletal and joint disorders Adult: Initial: 2.4-3.6 g/day in divided doses. Usual maintenance: 3.6-5.4 g/day. Monitor serum concentrations. Hepatic impairment: Severe liver disease: Not recommended
Alcohol, corticosteroids, analgin, phenylbutazone and oxyphenbutazone may increase risk of GI ulceration. Aspirin increases phenytoin levels. May antagonize actions of uricosurics and spironolactone. Potentially Fatal: May potentiate effects of anticoagulants, methotrexate and oral hypoglycaemics.
Patients with history of asthma, angioedema, urticaria or rhinitis, nasal polyp, severe renal or hepatic impairment, lactation. Lactation: Drug enters breast milk; decision should be made regarding whether to discontinue nursing or to discontinue drug, taking into account importance of drug to mother.
Pregnancy category: C; D in 3rd trimester
Aspirin is an analgesic, anti-inflammatory and antipyretic. It inhibits cyclooxygenase, which is responsible for the synthesis of prostaglandin and thromboxane. It also inhibits platelet aggregation.
PO Juvenile rheumatoid arthritis Child: <25 kg: 60-100 mg/kg/day PO divided q6-8hr (maintain serum salicylate at 150-300 mcg/mL) >25 kg: 2.4-3.6 g/day Pain & Fever <12 years 10-15 mg/kg PO q4hr, up to 60-80 mg/kg/day
Should be taken with food.
Fever, Headache, Pain/inflammation, Acute coronary syndrome, TIA, MI, Stroke
Renal impairment CrCl >10 mL/min: Dose adjustment not necessary CrCl <10 mL/min: Not recommended
GI disturbances; prolonged bleeding time, rhinitis, urticaria and epigastric discomfort; angioedema, salicylism, tinnitus; bronchospasm. Potentially Fatal: Gastric erosion, ulceration and bleeding; severe, occasionally fatal exacerbation of airway obstruction in asthma; Reye's syndrome (children <12 yr). Hepatotoxicity; CNS depression which may lead to coma; CV collapse and resp failure; paroxysmal bronchospasm and dyspnoea.
Hypersensitivity (attacks of asthma, angioedema, urticaria or rhinitis), active peptic ulceration; pregnancy (3rd trimester), children <12 yr, patients with haemophilia or haemorrhagic disorders, gout, severe renal or hepatic impairment, lactation.
